冠状动脉高血压剂量对冠状动脉内酸的反应
Walter A Parham1, Andre Bouhasin, Jeffrey P Ciaramita
1J. Gerard Mudd Cardiac Catheterization Laboratory, St Louis University Health Sciences Center, St Louis, Mo, USA.
Circulation
|March 3, 2004
概括
在心脏导管治疗期间,酸与腺相比,提供了相当但持续时间更长的冠状动脉高血压. 这种药物有效地刺激冠状动脉血流,没有不良的全身影响,使其适合生理测量.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 酸是急性冠状动脉干预中无回流现象的潜在治疗方法.
- 人类对冠心内尼托普鲁西德剂量反应和血液动力学影响的数据有限.
- 这项研究将心脏导管治疗的患者的冠心内酸与腺素进行比较.
研究的目的:
- 为了比较冠状动脉高血压和全身血动力学反应对冠状动脉内尼托普鲁西德与冠状动脉内腺素.
- 评估尼托普鲁西德在患有正常冠状动脉的患者的疗效和安全性.
- 评估酸作为高血压刺激剂的实用性,用于分量流量储备 (FFR) 测量.
主要方法:
- 在21名动脉正常的患者中测量了冠状动脉血流速度,心率和血压.
- 进行了冠心内尼特 (0.3-0.9μg/kg) 和腺 (30-50μg) 的连续剂量治疗.
- 分流储备 (FFR) 用两种药物测量了9名中级狭窄症患者.
主要成果:
- 冠内尼托普鲁西德诱导的冠状动脉高血压相当于腺,持续时间长25%.
- 高剂量的尼托普鲁西德 (0.9μg/kg) 导致静脉血压下降<20%,心率变化最小.
- 氨酸对全身血液动力学没有显著影响.
- 在和腺之间,FFR测量是相同的 (r=0.97).
结论:
- 在正常的冠状动脉中,冠状动脉内酸提供了与腺相等的,但比腺更持续的高血压反应.
- 尼特罗普鲁塞德,在用于无反流治疗的剂量中,可以实现持续的高血压,而没有有害的全身影响.
- 尼特罗普鲁塞德是冠状动脉生理学测量,包括FFR的可行的高血压刺激剂.
相关概念视频
01:17Antihypertensive Drugs: Action of β1 Blockers
2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
01:22Heart Failure Drugs: β-Blockers
2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K